{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:17:01Z","timestamp":1792815421975,"version":"4.5.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.annonc.2023.09.3103","type":"journal-article","created":{"date-parts":[[2023,12,10]],"date-time":"2023-12-10T10:55:59Z","timestamp":1702205759000},"page":"1131-1140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+\/HER2\u2212 breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2"],"prefix":"10.1016","volume":"34","author":[{"given":"S.","family":"Damodaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.C.","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Elkhanany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Barve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Blau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Cherian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Peguero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.P.","family":"Goetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.V.","family":"Plourde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.","family":"Portman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.C.F.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.annonc.2023.09.3103_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.annonc.2023.09.3103_bib2","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/1078-0432.CCR-18-2782","article-title":"Impact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: a population-based study using SEER Database","volume":"25","author":"Hwang","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.annonc.2023.09.3103_bib3","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"35","key":"10.1016\/j.annonc.2023.09.3103_bib4","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1200\/JCO.21.01392","article-title":"Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO Guideline Update","volume":"39","author":"Burstein","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2023.09.3103_bib5","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3390\/cancers11121894","article-title":"The emerging role of ESR1 mutations in luminal breast cancer as a prognostic and predictive biomarker of response to endocrine therapy","volume":"11","author":"De Santo","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.annonc.2023.09.3103_bib6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","article-title":"ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer","volume":"23","author":"Brett","year":"2021","journal-title":"Breast Cancer Res"},{"issue":"10","key":"10.1016\/j.annonc.2023.09.3103_bib7","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2016.1279","article-title":"Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial","volume":"2","author":"Chandarlapaty","year":"2016","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2023.09.3103_bib8","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/ng.2823","article-title":"Activating ESR1 mutations in hormone-resistant metastatic breast cancer","volume":"45","author":"Robinson","year":"2013","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.annonc.2023.09.3103_bib9","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/ng.2822","article-title":"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer","volume":"45","author":"Toy","year":"2013","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.annonc.2023.09.3103_bib10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ccell.2018.01.004","article-title":"Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations","volume":"33","author":"Jeselsohn","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.annonc.2023.09.3103_bib11","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1038\/s41467-022-29498-9","article-title":"ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2023.09.3103_bib12","series-title":"VERZENIO\u00ae (abemaciclib) tablets, for oral use Prescribing Information. Indianapolis","year":"2021"},{"key":"10.1016\/j.annonc.2023.09.3103_bib13","series-title":"IBRANCE\u00ae (palbociclib) tablets, for oral use Prescribing Information","year":"2019"},{"key":"10.1016\/j.annonc.2023.09.3103_bib14","series-title":"KISQALI\u00ae (ribociclib) tablets, for oral use Prescribing Information","year":"2022"},{"key":"10.1016\/j.annonc.2023.09.3103_bib15","unstructured":"IBRANCE (75, 100, 125 mg hard capsules) Summary of Product Characteristics. New York, NY: Pfizer."},{"key":"10.1016\/j.annonc.2023.09.3103_bib16","unstructured":"Kisqali (ribociclib) 200 mg film-coated tablets Summary of Product Characteristics. East Hanover, NJ: Novartis Pharmaceuticals Corporation."},{"key":"10.1016\/j.annonc.2023.09.3103_bib17","unstructured":"Verzenios (abemaciclib) 50, 100, 150 mg film-coated tablets Summary of Product Characteristics. Indianapolis, IN: Eli Lilly and Company."},{"key":"10.1016\/j.annonc.2023.09.3103_bib18","doi-asserted-by":"crossref","first-page":"pkad045","DOI":"10.1093\/jncics\/pkad045","article-title":"CDK4\/6 inhibitors: existing and emerging differences","volume":"7","author":"Johnston","year":"2023","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.annonc.2023.09.3103_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.693104","article-title":"Clinical and pharmacologic differences of CDK4\/6 inhibitors in breast cancer","volume":"11","author":"George","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.annonc.2023.09.3103_bib20","article-title":"Real-world treatment outcomes in HR+ HER2\u2212 metastatic breast cancer patients treated with CDK4\/6 inhibitors: results from a reference center in Brazil","volume":"35","author":"Queiroz","year":"2023","journal-title":"Cancer Treat Res Commun"},{"issue":"21","key":"10.1016\/j.annonc.2023.09.3103_bib21","doi-asserted-by":"crossref","first-page":"5388","DOI":"10.3390\/cancers14215388","article-title":"The renaissance of CDK inhibitors in breast cancer therapy: an update on clinical trials and therapy resistance","volume":"14","author":"Abdelmalak","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.annonc.2023.09.3103_bib22","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.chembiol.2019.05.005","article-title":"Multiomics profiling establishes the polypharmacology of FDA-approved CDK4\/6 inhibitors and the potential for differential clinical activity","volume":"26","author":"Hafner","year":"2019","journal-title":"Cell Chem Biol"},{"issue":"suppl 17","key":"10.1016\/j.annonc.2023.09.3103_bib23","doi-asserted-by":"crossref","first-page":"LBA1004","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1004","volume":"40","author":"Kalinsky","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2023.09.3103_bib24","first-page":"1","article-title":"Clinical outcomes with abemaciclib after prior CDK4\/6 inhibitor progression in breast cancer: a multicenter experience","author":"Wander","year":"2021","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"6","key":"10.1016\/j.annonc.2023.09.3103_bib25","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11912-020-00917-8","article-title":"Sequencing endocrine therapy for metastatic breast cancer: what do we do after disease progression on a CDK4\/6 inhibitor?","volume":"22","author":"Xi","year":"2020","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"10.1016\/j.annonc.2023.09.3103_bib26","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10549-022-06823-w","article-title":"Effect of prior treatments on post-CDK 4\/6 inhibitor survival in hormone receptor-positive breast cancer","volume":"197","author":"Franks","year":"2023","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.annonc.2023.09.3103_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clbc.2019.06.017","article-title":"Practical treatment strategies and future directions after progression while receiving CDK4\/6 inhibition and endocrine therapy in advanced HR(+)\/HER2(\u2212) breast cancer","volume":"20","author":"Sammons","year":"2020","journal-title":"Clin Breast Cancer"},{"issue":"11","key":"10.1016\/j.annonc.2023.09.3103_bib28","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2023.09.3103_bib29","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S1470-2045(20)30444-7","article-title":"Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial","volume":"21","author":"Turner","year":"2020","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.annonc.2023.09.3103_bib30","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.2016.67.3061","article-title":"Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer","volume":"34","author":"Fribbens","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 5","key":"10.1016\/j.annonc.2023.09.3103_bib31","first-page":"GS3","article-title":"Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: results of the randomized, multi-dose phase 2 SERENA-2 trial (Abstract GS3-02)","volume":"83","author":"Oliveira","year":"2023","journal-title":"Cancer Res"},{"issue":"28","key":"10.1016\/j.annonc.2023.09.3103_bib32","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD Trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2023.09.3103_bib33","series-title":"ORSERDU\u2122 (elacestrant) tablets, for oral use","year":"2023"},{"issue":"12","key":"10.1016\/j.annonc.2023.09.3103_bib34","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.20.03565","article-title":"Next-generation endocrine therapies for breast cancer","volume":"39","author":"McDonnell","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2023.09.3103_bib35","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221113694","article-title":"Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role","volume":"14","author":"Lloyd","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2023.09.3103_bib40","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1200\/JCO.2022.40.16_suppl.1032","article-title":"Serena-1: updated analyses from a Phase 1 study (parts C\/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer","volume":"40","author":"Oliveira","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 5","key":"10.1016\/j.annonc.2023.09.3103_bib41","first-page":"P3","article-title":"SERENA-1: updated analyses from a phase 1 study of the next generation oral selective estrogen receptor degrader camizestrant (AZD9833) combined with abemaciclib, in women with ER-positive, HER2-negative advanced breast cancer (Abstract P3-07-28)","volume":"83","author":"Turner","year":"2023","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2023.09.3103_bib42","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13058-021-01431-w","article-title":"Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer","volume":"23","author":"Lain\u00e9","year":"2021","journal-title":"Breast Cancer Res"},{"issue":"22","key":"10.1016\/j.annonc.2023.09.3103_bib43","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/jnci\/djq415","article-title":"Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women","volume":"102","author":"LaCroix","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"24","key":"10.1016\/j.annonc.2023.09.3103_bib44","first-page":"8683","article-title":"LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model","volume":"61","author":"Cohen","year":"2001","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.annonc.2023.09.3103_bib45","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1158\/1535-7163.MCT-19-1148","article-title":"The dysregulated pharmacology of clinically relevant ESR1 mutants is normalized by ligand-activated WT receptor","volume":"19","author":"Andreano","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.annonc.2023.09.3103_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.3104","article-title":"Lasofoxifene versus fulvestrant for ER+\/HER2- metastatic breast cancer with an ESR1 mutation: Results from the randomized, phase 2 ELAINE 1 trial.","author":"Goetz","year":"2023","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.annonc.2023.09.3103_bib47","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","article-title":"MONARCH 1, a phase ii study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR(+)\/HER2(\u2212) metastatic breast cancer","volume":"23","author":"Dickler","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2023.09.3103_bib48","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10549-022-06662-9","article-title":"nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR+, HER2\u2212 metastatic breast cancer","volume":"195","author":"Hamilton","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"34","key":"10.1016\/j.annonc.2023.09.3103_bib49","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2\u2212, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2023.09.3103_bib50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"NPJ Breast Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2023.09.3103_bib51","doi-asserted-by":"crossref","first-page":"e522","DOI":"10.1002\/onco.13691","article-title":"Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3","volume":"26","author":"Rugo","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2023.09.3103_bib52","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920963925","article-title":"MONARCH plus: abemaciclib plus endocrine therapy in women with HR+\/HER2\u2212 advanced breast cancer: the multinational randomized phase III study","volume":"12","author":"Zhang","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"25","key":"10.1016\/j.annonc.2023.09.3103_bib53","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2023.09.3103_bib54","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJMoa0808692","article-title":"Lasofoxifene in postmenopausal women with osteoporosis","volume":"362","author":"Cummings","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.annonc.2023.09.3103_bib55","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/01.gme.0000188736.69617.4f","article-title":"Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene","volume":"13","author":"McClung","year":"2006","journal-title":"Menopause"},{"key":"10.1016\/j.annonc.2023.09.3103_bib56","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2147\/TCRM.S5645","article-title":"Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis","volume":"5","author":"Lewiecki","year":"2009","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"10.1016\/j.annonc.2023.09.3103_bib57","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.2006.07.4393","article-title":"Incidence of venous thromboembolism and the impact on survival in breast cancer patients","volume":"25","author":"Chew","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2023.09.3103_bib58","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1185\/030079905X61839","article-title":"Safety assessment of raloxifene over eight years in a clinical trial setting","volume":"21","author":"Martino","year":"2005","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"10.1016\/j.annonc.2023.09.3103_bib59","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/jnci\/djk049","article-title":"Long-term results of tamoxifen prophylaxis for breast cancer \u2013 96-month follow-up of the randomized IBIS-I trial","volume":"99","author":"Cuzick","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.annonc.2023.09.3103_bib60","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.annonc.2023.09.3103_bib61","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s10549-018-05086-8","article-title":"Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors","volume":"174","author":"Xu","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"19","key":"10.1016\/j.annonc.2023.09.3103_bib62","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1200\/JCO.2003.10.111","article-title":"Inherited and acquired risk factors for venous thromboembolic disease among women taking tamoxifen to prevent breast cancer","volume":"21","author":"Duggan","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"10.1016\/j.annonc.2023.09.3103_bib63","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1161\/CIRCULATIONAHA.109.924571","article-title":"Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial","volume":"122","author":"Ensrud","year":"2010","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.annonc.2023.09.3103_bib64","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/jth.14630","article-title":"Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors","volume":"18","author":"Gervaso","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"issue":"17","key":"10.1016\/j.annonc.2023.09.3103_bib65","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/cncr.34367","article-title":"Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer","volume":"128","author":"Watson","year":"2022","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.annonc.2023.09.3103_bib66","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1158\/1078-0432.CCR-21-3811","article-title":"VERONICA: randomized phase II study of fulvestrant and venetoclax in ER-positive metastatic breast cancer post-CDK4\/6 inhibitors \u2013 efficacy, safety, and biomarker results","volume":"28","author":"Lindeman","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.annonc.2023.09.3103_bib67","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(21)00034-6","article-title":"Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study","volume":"22","author":"Rugo","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2023.09.3103_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1012391","article-title":"Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: a single institution experience","volume":"12","author":"Alaklabi","year":"2022","journal-title":"Front Oncol"},{"issue":"20","key":"10.1016\/j.annonc.2023.09.3103_bib69","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andre","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"42","key":"10.1016\/j.annonc.2023.09.3103_bib70","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.18632\/oncotarget.27770","article-title":"A\u00a0systematic review and meta-analysis of selected toxicity endpoints of alpelisib","volume":"11","author":"Shields","year":"2020","journal-title":"Oncotarget"},{"issue":"suppl 5","key":"10.1016\/j.annonc.2023.09.3103_bib71","first-page":"GS3","article-title":"Palbociclib after CDK4\/6i and endocrine therapy (PACE): a randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+\/HER2- metastatic breast cancer (Abstract GS3-06)","volume":"83","author":"Mayer","year":"2023","journal-title":"Cancer Res"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2023.09.3103_bib72","first-page":"1001","article-title":"Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])\/human epidermal growth factor receptor 2-negative (HER2[\u2212]) advanced breast cancer (ABC): PALMIRA trial","volume":"41","author":"Harper-Wynne","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2023.09.3103_bib73","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1158\/1078-0432.CCR-22-1281","article-title":"Palbociclib rechallenge for hormone receptor-positive\/HER-negative advanced breast cancer: findings from the phase II BioPER trial","volume":"29","author":"Albanell","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2023.09.3103_bib74","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1200\/PO.20.00345","article-title":"Longitudinal dynamics of circulating tumor cells and circulating tumor DNA for treatment monitoring in\u00a0metastatic breast cancer","volume":"5","author":"Gerratana","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2023.09.3103_bib75","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12885-017-3185-9","article-title":"Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging","volume":"17","author":"Garcia-Saenz","year":"2017","journal-title":"BMC Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753423039418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753423039418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T19:38:00Z","timestamp":1728070680000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753423039418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":71,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0923753423039418"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2023.09.3103","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+\/HER2\u2212 breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2023.09.3103","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2023.09.3104","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}